Jeff Packman
Chief Development Officer
Clementia Pharmaceuticals
Canada
Biography
Mr. Packman joined Clementia with more than two decades of international experience in regulatory affairs, manufacturing and clinical operations leadership, and orphan drug development. Mr. Packman has led drug development efforts at several biotechnology companies. Most recently, he served as chief development officer for Apofore Corporation, a start-up focused on the development of novel diabetes therapeutics. Prior to Apofore, Mr. Packman was Vice President of drug development operations at FoldRx Pharmaceuticals, which was acquired by Pfizer in October 2010. He was development team leader for Vyndaqel® (tafamidis), now approved in Europe for the treatment of the orphan disease transthyretin familial amyloid polyneuropathy. Mr. Packman has also headed development operations at Oscient Pharmaceuticals and worldwide business operations for the regulatory affairs division of PAREXEL International Corporation.
Research Interest
drug developement
